ea0042p20 | (1) | Androgens2016
McAllister Milly J
, McCall Pamela
, Underwood Mark A
, Leung Hing Y
, Edwards Joanne
Current therapies for locally advanced or metastatic prostate cancer aim to inhibit androgen receptor (AR) activation directly or by depleting androgens via androgen deprivation therapy. However this therapeutic approach eventually fails in ~80% of patients, leading to development of castrate resistant prostate cancer (CRPC). There are currently few therapeutic options available for CRPC with limited prognostic or predictive biomarkers. The aim of the current study was to dete...